Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Foley

Showing results (151-160 of 185) with videos related to

Pageof 19
Sort By:
The Australasian Journal of Dermatology|August 3, 2019
Atopic dermatitis in adults: An Australian management consensusSaxon Smith, Christopher Baker, Kurt Gebauer, et al.
The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Dermatology and Therapy|June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 TrialsChristopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.
The Journal of Clinical Endocrinology and Metabolism|December 9, 2014
Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologistsAnna L Mitchell, Linda Goss, Lemonia Mathiopoulou, et al.
Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Pageof 19

Showing results (151-160 of 185) with videos related to

Sort By:
Pageof 19
The Australasian Journal of Dermatology|August 3, 2019
Atopic dermatitis in adults: An Australian management consensusSaxon Smith, Christopher Baker, Kurt Gebauer, et al.
The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Dermatology and Therapy|June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 TrialsChristopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.
The Journal of Clinical Endocrinology and Metabolism|December 9, 2014
Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologistsAnna L Mitchell, Linda Goss, Lemonia Mathiopoulou, et al.
Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Pageof 19